{"nctId":"NCT00501631","briefTitle":"ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence","startDateStruct":{"date":"2007-07"},"conditions":["Alcohol Dependence"],"count":300,"armGroups":[{"label":"VIVITROL 380 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: VIVITROL 380 mg"]},{"label":"Placebo for VIVITROL 380 mg","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo for VIVITROL 380 mg"]}],"interventions":[{"name":"VIVITROL 380 mg","otherNames":["naltrexone for extended-release injectable suspension","Medisorb naltrexone"]},{"name":"Placebo for VIVITROL 380 mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Primary Inclusion Criteria:\n\n* Current diagnosis of alcohol dependence, meeting at least 5 of DSM-IV criteria\n* Expected to complete inpatient treatment for alcohol dependence within 24 hours of randomization\n* Must have 7-21 days, inclusive, of inpatient treatment for alcohol dependence prior to first dose\n* Negative urine toxicological screen for opioids on the day of randomization\n* Women of childbearing potential must agree to use an approved method of contraception for the study duration\n\nPrimary Exclusion Criteria:\n\n* Pregnancy or lactation\n* Evidence of hepatic failure including: ascites, bilirubin \\>10% above upper limit of normal and/or esophageal variceal disease\n* Current dependence (within the past year) to benzodiazepines, opioids or cocaine by DSM-IV criteria\n* Use of any opioids and/or methadone within 14 days prior to the screening visit, or subjects likely to require opioid therapy during the study period\n* Use of oral naltrexone, acamprosate, or disulfiram within 14 days prior to screening\n* Known intolerance and/or hypersensitivity to naltrexone, carboxymethylcellulose, or PLG\n* Parole, probation, or pending legal proceedings having the potential for incarceration during the study period","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Cumulative Percentage of Participants by Heavy Drinking Rate","description":"Cumulative percentage (%) of subjects reporting heavy drinking by category reflecting the various cut-offs for percentage of days that were heavy drinking days. A \"heavy drinking day\" was defined as 4 or more alcohol drinks in 1 day for women, and 5 or more alcohol drinks in 1 day for men. The Timeline Follow-Back (TLFB) method (Sobell \\& Sobell: Humana Press, 1992) was utilized to collect subjects' daily drinking information (ie, the number of drinks consumed per day per subject which was retrospectively recalled and recorded in a diary).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.8","spread":null},{"groupId":"OG001","value":"47.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.2","spread":null},{"groupId":"OG001","value":"59.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.8","spread":null},{"groupId":"OG001","value":"72.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.3","spread":null},{"groupId":"OG001","value":"79.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.9","spread":null},{"groupId":"OG001","value":"83.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.6","spread":null},{"groupId":"OG001","value":"85.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.9","spread":null},{"groupId":"OG001","value":"87.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.1","spread":null},{"groupId":"OG001","value":"89.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.4","spread":null},{"groupId":"OG001","value":"94.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.4","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Longer-term Safety of VIVITROL","description":"Number of subjects reporting at least 1 treatment-emergent adverse event (TEAE) while on study.","paramType":"NUMBER","dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":29,"n":152},"commonTop":["Injection site pain","Alcoholism","Headache","Nasopharyngitis","Nausea"]}}}